This segment focuses on the research and development of novel immunotherapies for the treatment of solid tumors. Turnstone Biologics is actively involved in preclinical and clinical studies, including Phase 1 trials for TIDAL-01, targeting various cancers such as breast, colorectal, head and neck, and uveal melanoma. The company utilizes oncolytic virus and TIL (tumor-infiltrating lymphocyte) therapies. Research and development activities include identifying and validating therapeutic targets, designing and synthesizing drug candidates, conducting preclinical studies to assess safety and efficacy, and managing clinical trials. The company's approach aims to harness the power of the immune system to recognize and eliminate cancer cells, potentially improving patient outcomes and offering new treatment options where current therapies are insufficient. The company is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. Partnerships with institutions like Moffitt Cancer Center are key to advancing research and clinical programs. The company's market positioning is in the competitive field of cancer immunotherapy, with a focus on innovative approaches to improve patient outcomes. Future opportunities include expanding the pipeline, securing regulatory approvals, and commercializing successful therapies.